Swiss National Bank increased its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) by 2.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 94,600 shares of the company’s stock after acquiring an additional 2,000 shares during the quarter. Swiss National Bank’s holdings in Amphastar Pharmaceuticals were worth $2,651,000 as of its most recent filing with the SEC.
Other large investors have also recently bought and sold shares of the company. Anfield Capital Management LLC increased its stake in shares of Amphastar Pharmaceuticals by 67.3% during the fourth quarter. Anfield Capital Management LLC now owns 1,027 shares of the company’s stock worth $29,000 after purchasing an additional 413 shares during the period. Point72 Hong Kong Ltd acquired a new stake in shares of Amphastar Pharmaceuticals during the first quarter worth $74,000. US Bancorp DE grew its stake in shares of Amphastar Pharmaceuticals by 23.2% in the third quarter. US Bancorp DE now owns 2,492 shares of the company’s stock valued at $70,000 after acquiring an additional 469 shares in the last quarter. Captrust Financial Advisors increased its position in Amphastar Pharmaceuticals by 114.4% during the first quarter. Captrust Financial Advisors now owns 2,770 shares of the company’s stock worth $99,000 after acquiring an additional 1,478 shares during the period. Finally, Dupont Capital Management Corp acquired a new stake in Amphastar Pharmaceuticals in the 4th quarter worth about $84,000. 61.72% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on shares of Amphastar Pharmaceuticals in a report on Thursday, May 18th. They set a “strong-buy” rating on the stock.
Amphastar Pharmaceuticals Price Performance
Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Rating) last released its earnings results on Tuesday, February 28th. The company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.34 by $0.33. Amphastar Pharmaceuticals had a net margin of 17.96% and a return on equity of 18.37%. The firm had revenue of $135.02 million for the quarter, compared to analyst estimates of $126.43 million. On average, analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 1.82 earnings per share for the current fiscal year.
Insider Buying and Selling at Amphastar Pharmaceuticals
In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 10,500 shares of the firm’s stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $44.35, for a total value of $465,675.00. Following the transaction, the chief financial officer now directly owns 105,148 shares of the company’s stock, valued at approximately $4,663,313.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, CFO William J. Peters sold 12,776 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, March 15th. The shares were sold at an average price of $36.43, for a total transaction of $465,429.68. Following the sale, the chief financial officer now directly owns 118,451 shares of the company’s stock, valued at approximately $4,315,169.93. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO William J. Peters sold 10,500 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $44.35, for a total transaction of $465,675.00. Following the sale, the chief financial officer now directly owns 105,148 shares in the company, valued at $4,663,313.80. The disclosure for this sale can be found here. Insiders have sold a total of 88,793 shares of company stock valued at $3,679,432 in the last ninety days. 27.80% of the stock is currently owned by company insiders.
Amphastar Pharmaceuticals Profile
Amphastar Pharmaceuticals, Inc engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments.
- Get a free copy of the StockNews.com research report on Amphastar Pharmaceuticals (AMPH)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating).
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.